Impact of new cyclooxygenase 2 inhibitors on human cytomegalovirus replication in vitro [0.03%]
新的环氧化酶2抑制剂对人巨细胞病毒体外复制的影响
D Andouard,R Gueye,S Hantz et al.
D Andouard et al.
Background: Human cytomegalovirus (HCMV) is involved in complications on immunocompromised patients. Current therapeutics are associated with several drawbacks, such as nephrotoxicity. ...
A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients [0.03%]
一项纳入定量抗HBc预测慢性乙肝患者(PegIFN治疗)疗效的模型
Yu-Qing Fang,Xiao-Yan Xu,Feng-Qin Hou et al.
Yu-Qing Fang et al.
Background: Few models to predict antiviral response of peginterferon were used in hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients and the prediction efficacy was unsatisfied. Quantitative antibody to ...
Topical cidofovir for benign human papillomavirus-associated skin lesions [0.03%]
topical cidofovir治疗良性人乳头瘤病毒相关皮肤病变
Larry Napolitano,Liesl Schroedl,Alexander Kerman et al.
Larry Napolitano et al.
Cidofovir is a broad-spectrum antiviral agent that has shown efficacy against skin lesions caused by human papillomavirus (HPV). We present a case of extensive verruca vulgaris lesions refractory to imiquimod that was responsive to topical ...
Comparison of three galenic forms of lamivudine in young West African children living with Human Immunodeficiency Virus [0.03%]
比较拉米夫定三种剂型在西非青年HIV感染者中的效果
Claire Pressiat,Evelyne Dainguy,Jean-Marc Tréluyer et al.
Claire Pressiat et al.
Background: Few pharmacokinetic data were reported on dispersible tablets despite their increasing use. One hundred fifty HIV-infected children receiving lamivudine were enrolled in the MONOD ANRS 12,206 trial. Three gale...
Rilpivirine plus cobicistat-boosted darunavir as alternative to standard three-drug therapy in HIV-infected, virologically suppressed subjects: Final results of the PROBE 2 trial [0.03%]
利匹韦林联合柯非齐增强型达芦那韦治疗艾滋病病毒感染且病毒学上抑制的患者：PROBE 2试验最终结果（与标准三联疗法相比）
Franco Maggiolo,Nicola Gianotti,Laura Comi et al.
Franco Maggiolo et al.
Background: Primary analysis at 24 weeks showed that switching to rilpivirine plus darunavir/cobicistat was non-inferior to continuing a standard three-drug antiretroviral regimen in virologically suppressed people with H...
Randomized Controlled Trial
Antiviral therapy. 2021 May;26(3-5):51-57. DOI:10.1177/13596535211042226 2021
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults [0.03%]
JNJ-64794964的I期研究：TLR-7激动剂在健康受试者中的安全性、耐受性、药代动力学及药效学研究
Edward Gane,Mina Pastagia,Ullrich Schwertschlag et al.
Edward Gane et al.
Background: This Phase I, two-part, first-in-human study assessed safety/tolerability and pharmacokinetics/pharmacodynamics of single-ascending doses (SAD) and multiple doses (MD) of the oral toll-like receptor-7 agonist,...
Low prevalence of doravirine-associated resistance mutations among polish human immunodeficiency-1 (HIV-1)-infected patients [0.03%]
多拉韦林耐药突变在波兰人类免疫缺陷病毒(HIV-1)感染者中很少见
Kaja Scheibe,Anna Urbańska,Paweł Jakubowski et al.
Kaja Scheibe et al.
Introduction: Doravirine (DOR) is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) that retains activity against common NNRTI resistance mutations. In this study, we aimed to investigate the prevalence of DO...
Evaluation of doravirine-based regimen population target in a large Italian clinical center [0.03%]
评估大型意大利临床中心基于 doravirine 基础方案的治疗人群目标
Damiano Farinacci,Arturo Ciccullo,Francesca Lombardi et al.
Damiano Farinacci et al.
Background: Doravirine (DOR) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) approved for HIV-1 infection treatment. Because of its genetic barrier, DOR appears to be a good alternative in switch strategies co...
Antonio Mastroianni,Valeria Vangeli,Sonia Greco et al.
Antonio Mastroianni et al.
Oseltamivir is an orally administered antiviral medication that selectively inhibits the influenza neuraminidase enzymes that are essential for viral replication and it is active against both influenza A and B viruses. Oseltamivir is indica...
Real-life findings on the impact of the COVID-19 pandemic on HIV care [0.03%]
关于新冠肺炎疫情对艾滋病治疗影响的实地研究发现
Arturo Ciccullo,Gianmaria Baldin,Alberto Borghetti et al.
Arturo Ciccullo et al.